Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial

被引:0
|
作者
Sacks, FM
Moyé, LA
Davis, BR
Cole, TG
Rouleau, JL
Nash, DT
Pfeffer, MA
Braunwald, E
机构
[1] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Univ Texas, Sch Publ Hlth, Houston, TX USA
[4] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada
[5] SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA
[6] Washington Univ, St Louis, MO USA
关键词
lipoproteins; cholesterol; coronary disease; drugs;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Although LDL lowering has been shown to reduce recurrent coronary events in patients with coronary heart disease, little direct information is available on the extent of LDL lowering required to achieve this outcome. Methods and Results-The Cholesterol and Recurrent Events (CARE) trial compared pravastatin and placebo in patients who had experienced myocardial infarction CMI) who had average concentrations of total cholesterol <240 mg/dL (baseline meant 209 mg/dL) and LDL cholesterol (LDL) 115 to 174 mg/dL (mean, 139 mg/dL). Pravastatin reduced coronary death or recurrent MI by 24%. In multivariate analysis, the LDL concentration achieved during follow-up was a significant, although nonlinear, predictor of the coronary event rate (P=.007), whereas the extent of LDL reduction was not significant, whether expressed as an absolute amount (P=.97) or a percentage (P=.76). The coronary event rate declined as LDL decreased during follow-up from 174 to approximate to 125 mg/dL, but no further decline was seen in the LDL range from 125 to 71 mg/dL, In multivariate analysis, triglyceride but not HDL concentrations during follow-up were weakly but significantly associated with the coronary event rate. Conclusions-The LDL concentrations achieved during treatment with pravastatin or placebo were associated with reduction in coronary events down to an LDL concentration of approximate to 125 mg/dL. LDL concentrations <125 mg/dL during treatment were not associated with further benefit, Absolute or percentage reduction in LDL had little relationship to coronary events.
引用
收藏
页码:1446 / 1452
页数:7
相关论文
共 50 条
  • [1] The influence of baseline lipid levels on reduction in coronary events by pravastatin: The Cholesterol and Recurrent Events trial
    Sacks, FM
    Wun, CC
    Cole, TG
    Nash, DT
    LePage, S
    Rouleau, J
    Moye, LA
    Davis, BR
    Pfeffer, MA
    Braunwald, E
    CIRCULATION, 1996, 94 (08) : 3152 - 3152
  • [2] Large LDL particle size predicts recurrent coronary events in patients with average LDL cholesterol concentrations in the CARE trial
    Campos, H
    Moye, LA
    Stampfer, MJ
    Glasser, S
    Sacks, FM
    CIRCULATION, 1999, 100 (18) : 739 - 739
  • [3] Apolipoprotein concentrations during treatment and recurrent coronary artery disease events
    van Lennep, JER
    Westerveld, HT
    van Lennep, HWRO
    Zwinderman, AH
    Erkelens, DW
    van der Wall, EE
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (11) : 2408 - 2413
  • [4] Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial
    Lewis, SJ
    Sacks, FM
    Mitchell, JS
    East, C
    Glasser, S
    Kell, S
    Letterer, R
    Limacher, M
    Moye, LA
    Rouleau, JL
    Pfeffer, MA
    Braunwald, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (01) : 140 - 146
  • [5] VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
    Sacks, FM
    Alaupovic, P
    Moye, LA
    Cole, TG
    Sussex, B
    Stampfer, MJ
    Pfeffer, MA
    Braunwald, E
    CIRCULATION, 2000, 102 (16) : 1886 - 1892
  • [6] Effect of Pravastatin Therapy on Coronary Events in Carriers of the KIF6 719Arg Allele from the Cholesterol and Recurrent Events Trial
    Shiffman, Dov
    Sabatine, Marc S.
    Louie, Judy Z.
    Kirchgessner, Todd G.
    Iakoubova, Olga A.
    Campos, Hannia
    Devlin, James J.
    Sacks, Frank M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (09): : 1300 - 1305
  • [7] Relationship Between LDL-C Reduction After Coronary Revascularization and Prevention of Recurrent Cardiovascular Events
    Nishiwaki, Tatsuhiro
    Kishi, Daisuke
    Yoshie, Fumihiko
    Fukuda, Keiko
    Ibuki, Chikao
    Seino, Yoshihiko
    Satoh, Mitsutoshi
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2010, 13 (02): : 254 - 262
  • [8] REDUCTION IN CORONARY EVENTS DURING TREATMENT WITH PRAVASTATIN
    FURBERG, CD
    PITT, B
    BYINGTON, RP
    PARK, JS
    MCGOVERN, ME
    AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (09): : C60 - C63
  • [9] Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range - Results of the cholesterol and recurrent events (CARE) trial
    Lewis, SJ
    Moye, LA
    Sacks, FM
    Johnstone, DE
    Timmis, G
    Mitchell, J
    Limacher, M
    Kell, S
    Glasser, SP
    Grant, J
    Davis, BR
    Pfeffer, MA
    Braunwald, E
    ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) : 681 - +
  • [10] The influence on coronary events of lipid therapy during treatment with pravastatin: The CARE trial
    Sacks, FM
    Moye, LA
    Davis, BR
    Rouleau, JL
    Pfeffer, MA
    Cole, TG
    Braunwald, E
    CIRCULATION, 1997, 96 (08) : 358 - 358